Bioceres Crop Solutions Corp.

What they do

Bioceres develops and commercializes agricultural inputs, including inoculants, biofertilizers, biostimulants, micro-beaded fertilizers, seed treatments, seeds (including the HB4 program), and crop protection products. The company operates mainly in Latin America (Argentina and Brazil) with additional presence in North America, Europe, the Middle East, and Africa. It is organized into three reportable segments: Crop Nutrition, Seed and Integrated Products, and Crop Protection.

Revenue drivers

• Crop Nutrition — Includes inoculants, biofertilizers, biostimulants, and micro-beaded fertilizers. It is a core segment, historically including the Syngenta upfront fee (FY2023) and continues to be a major revenue source.
• Seed and Integrated Products — Comprises seeds (including HB4 program) and seed treatment packs. Generates recurring revenue from seed sales and integrated technology packages, tied to the HB4 drought-tolerant trait program.
• Crop Protection — Includes bioprotection products, adjuvants, and other crop protection products and services. Provides revenue from both biological and conventional protection solutions.

Recent performance

For the fiscal year ended June 30, 2025, Bioceres reported total revenue of approximately $632.3 million, with a net loss of $0.02 per share. Revenue growth was driven by strong performance in Brazil and other regions, partially offset by lower sales in Argentina. The company recognized a one-time gain or revaluation related to its investment in Moolec Science S.A. in September 2025.

Strategy

Management focuses on expanding its HB4 drought-tolerant seed technology and integrated product offerings across key agricultural markets, particularly Brazil. The company continues to invest in R&D and additional production capacity, including a new manufacturing facility in Michigan. They also actively manage their portfolio through acquisitions and divestitures, such as the exchange of shares in Moolec Science S.A. The strategy emphasizes sustainable agriculture by combining biological inputs with traditional crop protection.

Risks

• Geographic concentration — A significant portion of revenue comes from Argentina and Brazil, making the company vulnerable to local economic, political, and currency volatility.
• Regulatory approval — The HB4 program and other biotech products require regulatory approvals in multiple countries; delays or denials could limit market access and revenue.
• Currency fluctuation — Most revenue is in Argentine pesos and Brazilian reais; depreciation of these currencies against the US dollar can reduce reported USD earnings.
• Customer concentration — Dependence on key distributors and large agricultural customers could lead to revenue loss if relationships are disrupted.

Outlook

Management expects continued growth in Brazil and other international markets, supported by the expansion of the HB4 program. They anticipate improved financial performance from cost efficiencies and product mix. The company also plans to capture synergies from recent investments and partnerships, including with Moolec Science. However, the outlook is tempered by ongoing macroeconomic challenges in Argentina.